Completed PHASE3 INTERVENTIONAL 2-arm NCT03751163

Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma

Randomized, Controlled, Double-blind Study of Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma

Sponsor: Fakultas Kedokteran Universitas Indonesia

Conditions Melasma

Interventions Hydroquinone 4% Cream Placebo Sunscreen Tranexamic Acid Oral Product

Updated 4 times since 2018 Last updated: Nov 21, 2018 Started: Mar 16, 2016 Primary completion: Apr 2, 2017 Completion: Apr 2, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03751163, this PHASE3 trial focuses on Melasma and remains completed. Sponsored by Fakultas Kedokteran Universitas Indonesia, it has been updated 4 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2018 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fakultas Kedokteran Universitas Indonesia

Data source: Fakultas Kedokteran Universitas Indonesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.